- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05677451
청소년에서 LOU064의 효능, PK, 안전성을 평가하기 위한 24주 이중 맹검 무작위 위약 대조 시험(12 -
만성 자발성 두드러기가 H1-항히스타민제로 적절하게 조절되지 않는 12세에서 18세 미만의 청소년을 대상으로 24주 동안 Remibrutinib(LOU064)의 효능, 약동학 및 안전성을 평가하기 위한 이중 맹검, 무작위, 위약 대조 임상시험 최대 추가 3년 동안 선택적인 공개 라벨 연장 및 최대 추가 3년 동안 선택적인 안전 장기 무치료 추적 기간
The purpose of this trial is:
- to assess the efficacy, pharmacokinetics, and safety of remibrutinib vs. placebo in adolescents from 12 to < 18 years of age suffering from chronic spontaneous urticaria inadequately controlled by H1-antihistamines
- to collect long-term efficacy, safety and tolerability data on remibrutinib in adolescents after having completed 24 weeks of treatment
- to collect safety data in this population for up to three years after the last dose of study treatment
연구 개요
상세 설명
This trial consists of 3 different periods:
- the "core period", which is randomized and double-blind, during which 2/3 participants will receive remibrutinib and 1/3 will receive placebo for 24 weeks. Total duration: approximately 32 weeks (10 site visits).
- an optional "open-label extension (OLE) period" proposed to all participants who completed 24 weeks of treatment of the "core period" and all scheduled assessments planned at week 24 visit . Depending on their CSU symptoms (as assessed by the doctor), participants will either receive remibrutinib for 24 weeks, or enter an observational treatment-free period for 1 year. If the CSU symptoms return during the observational period, the participants can switch to the treatment period at any time (decided by the doctor). At the end of the 24-week treatment period, if CSU is controlled, participants will enter the 1-year observational period, otherwise, they can continue with another cycle of 24-week remibrutinib treatment. The number of remibrutinib treatment or observational cycles will be limited to 6 times each. Total duration: from 1 year to approximately 3 years, and number of visits: from 3 to 15 (depending on the CSU symptoms).
- an optional "long-term treatment-free follow-up period" proposed to all participants who completed at least 4 months treatment in the "OLE period". No treatment will be given. Duration: 3 years with 1 site visit and up to 4 phone call follow-up visits.
The primary clinical question of interest is what is the effect of remibrutinib treatment versus placebo on the change from baseline in UAS7, ISS7 and HSS7 scores after 12 weeks of treatment
연구 유형
등록 (실제)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Cape Town, 남아프리카, 7925
- Novartis Investigative Site
-
-
Gauteng
-
Pretoria, Gauteng, 남아프리카, 0181
- Novartis Investigative Site
-
-
-
-
-
Utrecht, 네덜란드, 3584 CX
- Novartis Investigative Site
-
-
-
-
-
Berlin, 독일, 13353
- Novartis Investigative Site
-
Tübingen, 독일, 72076
- Novartis Investigative Site
-
-
Hesse
-
Frankfurt am Main, Hesse, 독일, 60590
- Novartis Investigative Site
-
-
-
-
Sarawak
-
Kuching, Sarawak, 말레이시아, 93586
- Novartis Investigative Site
-
-
-
-
California
-
Bakersfield, California, 미국, 93301
- Kern Research
-
San Diego, California, 미국, 92123
- Allergy and Asthma Medical Group and Research Center
-
-
Florida
-
Miami, Florida, 미국, 33156
- Pediatric Dermatology of Miami at the Pediatric CoE
-
-
Idaho
-
Boise, Idaho, 미국, 83706
- Treasure Valley Medical Research
-
-
Illinois
-
Glenview, Illinois, 미국, 60077
- Endeavor Health
-
-
Kentucky
-
Owensboro, Kentucky, 미국, 42301
- Allergy and Asthma Specialist P S C
-
-
Ohio
-
Toledo, Ohio, 미국, 43617
- Toledo Institute of Clinical Research
-
-
Oklahoma
-
Oklahoma City, Oklahoma, 미국, 73120
- Allergy Asthma and Clinical Research
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, 미국, 15241
- Allergy and Clinical Immunology Associates
-
-
Texas
-
San Antonio, Texas, 미국, 78213
- RFSA Dermatology
-
-
Utah
-
Sandy City, Utah, 미국, 84093
- Allergy Associates of Utah
-
-
-
-
-
Valencia, 스페인, 46014
- Novartis Investigative Site
-
-
Barcelona
-
Esplugues, Barcelona, 스페인, 08950
- Novartis Investigative Site
-
-
-
-
-
CABA, 아르헨티나, C1181ACH
- Novartis Investigative Site
-
San Miguel de Tucumán, 아르헨티나, T4000AXL
- Novartis Investigative Site
-
-
Buenos Aires
-
CABA, Buenos Aires, 아르헨티나, C1414AIF
- Novartis Investigative Site
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, 아르헨티나, S2000DEJ
- Novartis Investigative Site
-
-
-
-
-
Manchester, 영국, M13 9WL
- Novartis Investigative Site
-
Southampton, 영국, SO16 6YD
- Novartis Investigative Site
-
-
Cambridgeshire
-
Peterborough, Cambridgeshire, 영국, PE3 9GZ
- Novartis Investigative Site
-
-
-
-
FI
-
Florence, FI, 이탈리아, 50139
- Novartis Investigative Site
-
-
PV
-
Pavia, PV, 이탈리아, 27100
- Novartis Investigative Site
-
-
SI
-
Siena, SI, 이탈리아, 53100
- Novartis Investigative Site
-
-
-
-
Fukuoka
-
Kitakyushu, Fukuoka, 일본, 8078556
- Novartis Investigative Site
-
-
Kumamoto
-
Kamimashi-gun, Kumamoto, 일본, 8613106
- Novartis Investigative Site
-
-
Osaka
-
Sakai, Osaka, 일본, 5938324
- Novartis Investigative Site
-
-
Shimane
-
Izumo, Shimane, 일본, 6938501
- Novartis Investigative Site
-
-
Tokyo
-
tabashi City, Tokyo, 일본, 1738610
- Novartis Investigative Site
-
-
-
-
-
Beijing, 중국, 100050
- Novartis Investigative Site
-
Beijing, 중국, 100069
- Novartis Investigative Site
-
-
Guangdong
-
Guangzhou, Guangdong, 중국, 510091
- Novartis Investigative Site
-
-
Sichuan
-
Chengdu, Sichuan, 중국, 610041
- Novartis Investigative Site
-
-
-
-
Santiago Metropolitan
-
Santiago, Santiago Metropolitan, 칠레, 8420383
- Novartis Investigative Site
-
-
-
-
Quebec
-
Montreal, Quebec, 캐나다, H4A 3J1
- Novartis Investigative Site
-
-
-
-
-
Bangkok, 태국, 10330
- Novartis Investigative Site
-
Bangkok, 태국, 10700
- Novartis Investigative Site
-
-
Hat Yai
-
Songkhla, Hat Yai, 태국, 90110
- Novartis Investigative Site
-
-
-
-
-
Adana, 터키 (Türkiye), 01330
- Novartis Investigative Site
-
-
Fatih
-
Istanbul, Fatih, 터키 (Türkiye), 34093
- Novartis Investigative Site
-
-
Sihhiye Altindag
-
Ankara, Sihhiye Altindag, 터키 (Türkiye), 06230
- Novartis Investigative Site
-
-
-
-
-
Lodz, 폴란드, 90-436
- Novartis Investigative Site
-
-
-
-
Hong Kong
-
Hong Kong, Hong Kong, 홍콩, 999077
- Novartis Investigative Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Key Inclusion Criteria:
- Male and female adolescent participants aged >= 12 to < 18 years of age at the time of signing the informed consent
- CSU duration for >= 6 months prior to screening (defined as the onset of CSU determined by the investigator based on all available supporting documentation)
- Diagnosis of CSU inadequately controlled by second-generation H1-AH at the time of randomization defined as:
- The presence of itch and hives for ≥ 6 consecutive weeks prior to screening despite the use of second-generation H1-AH during this time period according to local treatment guidelines
- UAS7 score (range 0 - 42) >= 16, ISS7 score (range 0 - 21) >= 6 and HSS7 score (range 0 - 21) >= 6 during the 7 days prior to randomization (Day 1)
- Documentation of hives within three months before randomization (either at screening and/or at randomization; or documented in the participants' medical history)
Key Exclusion criteria:
- Previous use of remibrutinib or other BTK inhibitors
- Significant bleeding risk or coagulation disorders
- History of gastrointestinal bleeding
- Requirement for anti-platelet medication, except for acetylsalicylic acid up to 100 mg/d or clopidogrel up to 75 mg/d. The use of dual anti-platelet therapy (e.g., acetylsalicylic acid + clopidogrel) is prohibited
- History or current hepatic disease
- Evidence of clinically significant cardiovascular, neurological, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, hematological disorders, gastrointestinal disease or immunodeficiency that, in the investigator's opinion, would compromise the safety of the participant, interfere with the interpretation of the study results or otherwise preclude participation or protocol adherence of the participant
- History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar chemical classes
- Participants having a clearly defined predominant or sole trigger of their chronic urticaria (chronic inducible urticaria) including urticaria factitia (symptomatic dermographism), cold-, heat-, solar-, pressure-, delayed pressure-, aquagenic-, cholinergic-, or contact-urticaria
- Other diseases with symptoms of urticaria or angioedema, including but not limited to urticaria vasculitis, urticaria pigmentosa, erythema multiforme, mastocytosis, hereditary angioedema, or drug-induced urticaria
- Any other skin disease associated with chronic itching that might influence in the investigator's opinion the study evaluations and results, e.g., atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus or psoriasis
Other protocol-defined inclusion/exclusion criteria may apply.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Arm 1: LOU064 (blinded)
LOU064 (blinded) taken orally b.i.d. for 24 weeks, followed by LOU064 (open-label) taken orally b.i.d. for up to 6 cycles of 24 weeks. |
LOU064 (blinded) active treatment
다른 이름들:
|
|
위약 비교기: Arm 2: LOU064 placebo (blinded)
LOU064 placebo (blinded) taken orally b.i.d. for 24 weeks (randomized in a 2:1 ratio arm 1: arm 2) |
matching active drug |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change from baseline in UAS7
기간: Baseline, week 12
|
The Urticaria Activity Score (UAS) is sum of the Hive Severity Score (HSS) and the Itch Severity Score (ISS). UAS7 is sum of the HSS7 and the ISS7 scores. Possible range of weekly UAS7 score is 0 to 42. Complete UAS7 response is UAS7 = 0. Negative change from baseline indicates improvement. |
Baseline, week 12
|
|
Change fron baseline in ISS7
기간: Baseline, Week 12
|
Itch Severity Score (ISS) scale is 0 to 3. Score (ISS7) is derived by adding up average daily scores of 7 days preceding visit. Possible range of weekly score is therefore 0 to 21. Itch Severity Score scale: 0 - None 1 - Mild (minimal awareness, easily tolerated) 2 - Moderate (definite awareness, bothersome but tolerable) 3 - Severe (difficult to tolerate). Negative change from baseline indicates improvement. |
Baseline, Week 12
|
|
Change from baseline in HSS7
기간: Baseline, Week 12
|
Hives Severity Score (HSS) scale is 0 to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. Possible range of the weekly score is therefore 0 to 21. Hives Severity Score scale: 0 - None 1 - Mild (1-6 hives/12 hours) 2 - Moderate (7-12 hives/12 hours) 3 - Severe (>12 hives/12 hours). Negative change from baseline indicates improvement. |
Baseline, Week 12
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Cmax of remibrutinib
기간: At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake
|
The maximum (peak) observed blood drug concentration after single dose administration |
At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake
|
|
Tmax of remibrutinib
기간: At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake
|
The time to reach maximum (peak) blood drug concentration after single dose administration |
At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake
|
|
AUClast of remibrutinib
기간: At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake
|
The Area Under the Curve (AUC) from pre-dose to the last measurable concentration sampling time |
At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake
|
|
Absolute change from baseline in ISS7
기간: Baseline - Week 12
|
Itch Severity Score (ISS) scale is 0 to 3. Score (ISS7) is derived by adding up average daily scores of 7 days preceding visit. Possible range of weekly score is therefore 0 to 21. Itch Severity Score scale: 0 - None 1 - Mild (minimal awareness, easily tolerated) 2 - Moderate (definite awareness, bothersome but tolerable) 3 - Severe (difficult to tolerate). Negative change from baseline indicates improvement. |
Baseline - Week 12
|
|
Absolute change from baseline in HSS7
기간: Baseline - Week 12
|
Hives Severity Score (HSS) scale is 0 to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. Possible range of the weekly score is therefore 0 to 21. Hives Severity Score scale: 0 - None 1 - Mild (1-6 hives/12 hours) 2 - Moderate (7-12 hives/12 hours) 3 - Severe (>12 hives/12 hours). Negative change from baseline indicates improvement. |
Baseline - Week 12
|
|
Achievement of UAS7 ≤ 6 (yes/no)
기간: Week 12 and over time
|
Disease activity control is defined as UAS7 ≤ 6. The Urticaria Activity Score (UAS) is sum of the Hive Severity Score (HSS) and the Itch Severity Score (ISS). UAS7 is sum of the HSS7 and the ISS7 scores. Possible range of weekly UAS7 score is 0 to 42. |
Week 12 and over time
|
|
Achievement of UAS7 = 0 (yes/no)
기간: Week 12 and over time
|
Complete absence of hives and itch is defined as UAS7 = 0. The Urticaria Activity Score (UAS) is sum of the Hive Severity Score (HSS) and the Itch Severity Score (ISS). UAS7 is sum of the HSS7 and the ISS7 scores. Possible range of weekly UAS7 score is 0 to 42. |
Week 12 and over time
|
|
Absolute change from baseline in CDLQI score
기간: Week 12
|
The Children Dermatology life Quality Index (CDLQI) score range is 0 to 30, with 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life). |
Week 12
|
|
Number of weeks without angioedema, assessed by the cumulative number of weeks with an AAS7 = 0 response
기간: baseline - Week 12
|
Angioedema Activity Score (AAS7) is a measure of the frequency and intensity of angioedema episodes. The total possible range of scores over 7 days is 0-105 where higher scores indicate increased angioedema activity. |
baseline - Week 12
|
|
Occurrence of treatment-emergent adverse events (AE) and serious adverse events (SAE) during the core period
기간: 28 weeks
|
To demonstrate the safety and tolerability of remibrutinib by assessing occurrence of treatment emergent adverse events and serious adverse events during the core period of the study. |
28 weeks
|
|
Occurrence of treatment emergent AEs, and SAEs during the Open Label Extension (OLE) period
기간: 3 years
|
To demonstrate the safety and tolerability of remibrutinib by assessing occurrence of treatment emergent adverse events and serious adverse events during the OLE period of the study. |
3 years
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Novartis Pharmaceuticals, Novartis Pharmaceuticals
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- CLOU064F12301
- 2022-502159-78-00 (기타 식별자: EU CT Number)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .